Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Efficacy Study of LB80380 in the Treatment-naive Patients of Chronic Hepatitis B
This study has been completed.
Study NCT01026610   Information provided by LG Life Sciences

First Received on December 3, 2009.   Last Updated on October 4, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Chronic Hepatitis B
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis B, Chronic
Hepatitis, Chronic
More general conditions related to this trial
Digestive System Diseases
DNA Virus Infections
Enterovirus Infections
Hepadnaviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Interventions listed in this trial
LB80380 90 mg
LB80380 150 mg
entecavir 0.5 mg
Additional drug interventions recognized in this trial
Entecavir
More general drug interventions related to this trial
Anti-Infective Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
LG Life Sciences


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services